검색어: populacijska (슬로베니아어 - 영어)

populacijska krivulja
population curve

primerjalna genomika in populacijska genetika;
comparative genomics and population genetics;

populacijska analiza ni pokazala vpliva rase.
no effect of race was identified in the population analysis.

populacijska farmakokinetična analiza pri posebnih populacijah
population pharmacokinetic analysis in special populations

1.1 populacijska gibanja:staranje še vedno izziv
1.1 population trends: the ageing challenge persists

pri vzpostavitvi takih zbiralnih točk se mora upoštevati dostopnost in populacijska gostota.
the establishment of such collection points must take into account accessibility and population density.

populacijska farmakokinetična analiza kaže, da starost nima pomembnega vpliva na farmakokinetiko vemurafeniba.
based on the population pk analysis, age has no statistically significant effect on vemurafenib pharmacokinetics.

populacijska farmakokinetika kaže, da spol ne vpliva bistveno na izločanje ibrutiniba iz krvnega obtoka.
population pharmacokinetics data indicated that gender does not significantly influence ibrutinib clearance from the circulation.

genska raznolikost vrst kot tudi zadovoljiva populacijska raven ter njihova območja za razmnoževanje in habitate,
the genetic diversity, as well as satisfactory population levels, of species, and their breeding grounds and habitats,

poleg tega populacijska študija fk ni pokazala korelacije med fk parametri netupitanta in markerji disfunkcije ledvic.
furthermore, the population pk study showed no correlation between pk parameters of netupitant and markers of renal dysfunction.

populacijska farmakokinetična analiza je bila opravljena z uporabo redko vzorčenih serumskih koncentracij iz štirih kontroliranih kliničnih preskušanj.
population pharmacokinetic analysis was performed using sparsely sampled serum concentration values from four controlled clinical trials.

populacijska farmakokinetična analiza je pokazala, da lahko prisotnost opioida poveča izpostavljenost za približno 11 %.
based on population pharmacokinetic analysis, the presence of an opioid appeared to increase exposure by about 11%.

spol populacijska analiza farmakokinetike je pokazala nekoliko večjo izpostavljenost darunavirju pri ženskah, okuženih s hiv, kot pri moških.
gender population pharmacokinetic analysis showed a slightly higher darunavir exposure in hiv infected females compared to males.

populacijska vsota vrednosti Ŷ za znesek novih poslov se nato oceni na podlagi naslednjega splošnega obrazca( 1):
the population total Ŷ for the amount of new business shall then be estimated by means of the following generic formula( 2):

populacijska farmakokinetična analiza je pokazala, da se je navidezni peroralni očistek empagliflozina zmanjšal z zmanjšanjem egfr, kar je povzročilo večjo izpostavljenost zdravilu.
the population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased with a decrease in egfr leading to an increase in drug exposure.

populacijska analiza kaže, da starost v preskušanem razponu (21 do 75 let) bistveno ne spremeni farmakokinetike zdravila caelyx.
population based analysis demonstrates that age across the range tested (21–75 years) does not significantly alter the pharmacokinetics of caelyx.

populacijska farmakokinetična analiza je zajela 927 bolnikov z rakom (764 z nsclc), ki so se zdravili z monoterapijo z zdravilom giotrif.
a population pharmacokinetic analysis was performed in 927 cancer patients (764 with nsclc) receiving giotrif monotherapy.

populacijska analiza farmakokinetike je pokazala nekoliko večjo izpostavljenost darunavirju (16,8 %) pri ženskah, okuženih s hiv, kot pri moških.
population pharmacokinetic analysis showed a slightly higher darunavir exposure (16.8%) in hiv infected females compared to males.

populacijska farmakokinetična analiza nakazuje, da starost nima klinično pomembnega vpliva na farmakokinetiko trastuzumaba emtanzina (glejte poglavji 5.1 in 5.2).
population pharmacokinetic analysis indicates that age does not have a clinically meaningful effect on the pharmacokinetics of trastuzumab emtansine (see sections 5.1 and 5.2).

populacijska farmakokinetična analiza ceftolozana/tazobaktama ni pokazala klinično pomembnih razlik auc ceftolozana (116 moških v primerjavi s 70 ženskami) in tazobaktama (80 moških v primerjavi s 50 ženskami).
in a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in auc were observed for ceftolozane (116 males compared to 70 females) and tazobactam (80 males compared to 50 females).